CJC-1295 with DAC
CJC-1295 DAC / Drug Affinity Complex CJC-1295
CJC-1295 with DAC is a long-acting GHRH analog that binds to albumin in the blood. In 2006 human trials, one injection raised GH 2–10-fold for 6+ days and IGF-1 1.5–3-fold for 9–11 days, with a half-life of 5.8–8.1 days; GH pulses were preserved. It is not FDA-approved.
Half-life
6–8 days
Typical Dose
1–2 mg per week
1.2/2Route
subcutaneous
Category
growth_hormone
Evidence Overview
Strength of evidence across clinical, expert, and experimental lanes.
How CJC-1295 with DAC is dosed in practice
Usually taken by subcutaneous (SubQ) injection. Typical range: 1–2 mg per week. Half-life: 6–8 days. Each card gives the dose, frequency and duration from one evidence lane: Clinical (human trials), Expert (practitioner protocols) or Experimental (early or animal data). These ranges describe what has been studied or used; they are not a prescription.
Work out the units to draw with the reconstitution calculator, how long a vial lasts with the vial duration calculator, and how levels fall between doses with the half-life calculator.
Two randomized, placebo-controlled, ascending-dose trials in healthy adults (2006): after a single SubQ injection, mean GH rose 2–10-fold for 6 days or more and IGF-1 rose 1.5–3-fold for 9–11 days; estimated half-life was 5.8–8.1 days. With repeated weekly or every-other-week doses, IGF-1 stayed above baseline for up to 28 days. No serious adverse reactions were reported; 30 and 60 mcg/kg doses were best tolerated. A follow-up study in men (2006) found GH pulse frequency and size were unchanged while trough GH rose about 7.5-fold.
- Randomized placebo-controlled trials in healthy adults (2006)
- Human GH-pulsatility study (2006)
Many practitioners prefer the no-DAC version for more physiological pulsatile GH release. The DAC version is chosen by patients who want fewer injections. Dose 1 mg twice weekly or 2 mg once weekly. Monitor IGF-1, fasting glucose, and prolactin.
- Practitioner protocols
Community generally prefers the no-DAC version for bodybuilding due to more natural GH pulses. DAC version popular among those prioritizing convenience. Some report water retention, numbness/tingling in extremities, and increased hunger.
- Community self-reports
Unlock Full Evidence Sources
Get complete clinical data, expert protocols, and experimental research for CJC-1295 with DAC and 90+ other compounds with Pro.
Upgrade to ProInteraction Network
Known interactions with other compounds. Click nodes to explore connections.
Safety & Contraindications
- Active cancer or history of cancer (GH axis stimulation)
- Diabetes (may worsen insulin resistance)
- Pregnancy or breastfeeding
- Pituitary tumors or disorders
CJC-1295 with DAC: common questions
What is CJC-1295 with DAC?
CJC-1295 with DAC is a long-acting GHRH analog that binds to albumin in the blood. In 2006 human trials, one injection raised GH 2–10-fold for 6+ days and IGF-1 1.5–3-fold for 9–11 days, with a half-life of 5.8–8.1 days; GH pulses were preserved. It is not FDA-approved.
How is CJC-1295 with DAC dosed?
CJC-1295 with DAC is usually taken by subcutaneous (SubQ) injection. Typical range in DoseCraft's library: 1–2 mg per week. Clinical (human trials): 30–60 mcg/kg SubQ per dose (up to 90 mcg/kg in one study); Single dose, or 2–3 doses given weekly or every other week; Single doses to a few weeks. Expert (practitioner protocols): 1–2 mg weekly; 1–2x per week; 8–12 week cycles. Experimental (early or animal data): 2 mg once weekly or 1 mg twice weekly; 1–2x weekly; 8–16 weeks. These ranges describe what has been studied or used; they are not a prescription.
Is CJC-1295 with DAC FDA-approved?
No. CJC-1295 with DAC is not approved by the FDA for any use in people.
What is the half-life of CJC-1295 with DAC?
DoseCraft's library lists a half-life of 6–8 days. Half-life sets how often a compound is dosed and how long it takes to clear: about five half-lives.
Who should not use CJC-1295 with DAC?
Listed contraindications: Active cancer or history of cancer (GH axis stimulation); Diabetes (may worsen insulin resistance); Pregnancy or breastfeeding; Pituitary tumors or disorders.
Free Guides for CJC-1295 with DAC
Information is for educational purposes only. Always consult a licensed healthcare provider before starting any peptide regimen.
Page updated . How we grade evidence: methodology.